HIFs and tumors - Causes and consequences

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 286, Issue 4 55-4, 2004, Pages

  Höpfl, Gisele ^a   Ogunshola, Omolara ^a   Gassmann, Max ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Cancer; Hypoxia; Oncogenes; Oxygen sensing; Vasculature

Indexed keywords

ANGIOGENESIS INHIBITOR; GELDANAMYCIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; KF 58333; OXYGEN; PROTEIN SUBUNIT; RADICICOL; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CARCINOGENESIS; CELL SURVIVAL; DRUG TARGETING; GENE ACTIVATION; GENE OVEREXPRESSION; GENE STRUCTURE; GENE TARGETING; GLUCOSE METABOLISM; HUMAN; HYDROXYLATION; HYPOXIA; MICROTUBULE ORGANIZING CENTER; NONHUMAN; ONCOGENE; OXYGEN TENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN TARGETING; REVIEW; SEQUENCE HOMOLOGY; TISSUE OXYGENATION; TUMOR; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 1642416042     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.00538.2003     Document Type: Review

References (268)

1. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, and Semenza GL. Expression of hypoxia-inducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61: 2911-2916, 2001.
2. Agani F, Kirsch DG, Friedman SL, Kastan MB, and Semenza GL. p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene. Cancer Res 57: 4474-4477, 1997.
3. Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J, Niizeki H, Kawamura K, Hosokawa M, and Asaka M. Constitutive expression of hypoxia-inducible factor-1α renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 61: 6548-6554, 2001.
4. Alfranca A, Gutierrez MD, Vara A, Aragones J, Vidal F, and Landazuri MO. c-Jun and hypoxia-inducible factor 1 functionally cooperate in hypoxia-induced gene transcription. Mol Cell Biol 22: 12-22, 2002.
5. Alvarez-Tejado M, Alfranca A, Aragones J, Vara A, Landazuri MO, and del Peso L. Lack of evidence for the involvement of the phosphoinositide 3-kinase/Akt pathway in the activation of hypoxia-inducible factors by low oxygen tension. J Biol Chem 277: 13508-13517, 2002.
6. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, and Neckers LM. Stabilization of wild-type p53 by hypoxia-inducible factor 1α. Nature 392: 405-408, 1998.
7. 2-dependent degradation domain of hypoxia inducible factor-1α (HIF-1α). J Cancer Res Clin Oncol 128: 358-362, 2002.
8. Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA, Bunn HF, and Livingston DM. An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci USA 93: 12969-12973, 1996.
9. Arsham AM, Plas DR, Thompson CB, and Simon MC. Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1α nor sufficient for HIF-1-dependent target gene transcription. J Biol Chem 277: 15162-15170, 2002.
10. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, and Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89: 1175-1184, 1997.
11. Beasley NJ, Leek R, Alam M, Turley H, Cox GJ, Gatter K, Millard P, Fuggle S, and Harris AL. Hypoxia-inducible factors HIF-1α and HIF-2α in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 62: 2493-2497, 2002.
12. Beasley NJ, Wykoff CC, Watson PH, Leek R, Turley H, Gatter K, Pastorek J, Cox GJ, Ratcliffe P, and Harris AL. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 61: 5262-5267, 2001.
13. Bhattacharya S, Michels CL, Leung MK, Arany ZP, Kung AL, and Livingston DM. Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. Genes Dev 13: 64-75, 1999.
14. Bilton RL and Booker GW. The subtle side to hypoxia inducible factor (HIFα) regulation. Eur J Biochem 270: 791-798, 2003.
15. Binley K, Askham Z, Martin L, Spearman H, Day D, Kingsman S, and Naylor S. Hypoxia-mediated tumour targeting. Gene Ther 10: 540-549, 2003.
16. Birner P, Gatterbauer B, Oberhuber G, Schindl M, Rossler K, Prodinger A, Budka H, and Hainfellner JA. Expression of hypoxia-inducible factor-1α in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 92: 165-171, 2001.
17. Birner P, Schindl M, Obermair A, Breitenecker G, and Oberhuber G. Expression of hypoxia-inducible factor 1α in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7: 1661-1668, 2001.
18. Blagosklonny MV, An WG, Romanova LY, Trepel J, Fojo T, and Neckers L. p53 inhibits hypoxia-inducible factor-stimulated transcription. J Biol Chem 273: 11995-11998, 1998.
19. Blancher C, Moore JW, Robertson N, and Harris AL. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1α, HIF-2α, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res 61: 7349-7355, 2001.
20. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, and van der Wall E. Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97: 1573-1581, 2003.
21. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, and van der Wall E. Levels of hypoxia-inducible factor-1α during breast carcinogenesis. J Natl Cancer Inst 93: 309-314, 2001.
22. Boucher Y, Kirkwood JM, Opacic D, Desantis M, and Jain RK. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 51: 6691-6694, 1991.
23. Bouvet M, Ellis LM, Nishizaki M, Fujiwara T, Liu W, Bucana CD, Fang B, Lee JJ, and Roth JA. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits a-ngiogenesis in human colon cancer. Cancer Res 58: 2288-2292, 1998.
24. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, and Dewhirst MW. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56: 941-943, 1996.
25. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, and Schreiber SL. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 377: 441-446, 1995.
26. Brown JM and Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58: 1408-1416, 1998.
27. Bruick RK. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA 97: 9082-9087, 2000.
28. Bruick RK and McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294: 1337-1340, 2001.
29. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA, and Belldegrun AS. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9: 802-811, 2003.
30. Burroughs KD, Oh J, Barrett JC, and DiAugustine RP. Phosphatidylinositol 3-kinase and mek1/2 are necessary for insulin-like growth factor-I-induced vascular endothelial growth factor synthesis in prostate epithelial cells: a role for hypoxia-inducible factor-1? Mol Cancer Res 1: 312-322, 2003.
31. Camenisch G, Stroka DM, Gassmann M, and Wenger RH. Attenuation of HIF-1 DNA-binding activity limits hypoxia-inducible endothelin-1 expression. Pflügers Arch 443: 240-249, 2001.
32. Carmeliet P, Dor Y, Herbert J-M, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, and Keshet E. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394: 485-490, 1998.
33. Carmeliet P and Jain RK. Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
34. Cerrero P, Okamoto K, Coumailleau P, O'Brien S, Tanaka H, and Poellinger L. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1α. Mol Cell Biol 20: 402-415, 2000.
35. Chan DA, Sutphin PD, Denko NC, and Giaccia AJ. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1α. J Biol Chem 277: 40112-40117, 2002.
36. Chang H, Shyu KG, Lee CC, Tsai SC, Wang BW, Hsien Lee Y, and Lin S. GL331 inhibits HIF-1α expression in a lung cancer model. Biochem Biophys Res Commun 302: 95-100, 2003.
37. Chen C, Pore N, Behrooz A, Ismail-Beigi F, and Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 276: 9519-9525, 2001.
38. Chen D, Li M, Luo J, and Gu W. Direct interactions between HIF-1α and Mdm2 modulate p53 function. J Biol Chem 278: 13595-13598, 2003.
39. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P, and Harris AL. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 19: 3660-3668, 2001.
40. Chilov D, Camenisch G, Kvietikova I, Ziegler U, Gassmann M, and Wenger RH. Induction and nuclear translocation of hypoxia-inducible factor-1 (HIF-1): heterodimerization with ARNT is not necessary for nuclear accumulation of HIF-1 alpha. J Cell Sci 112: 1203-1212, 1999.
41. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, and Maxwell PH. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275: 25733-25741, 2000.
42. Conrad PW, Rust RT, Han J, Millhorn DE, and Beitner-Johnson D. Selective activation of p38α and p38γ by hypoxia role in regulation of cyclin D1 by hypoxia in PC12 cells. J Biol Chem 274: 23570-23576, 1999.
43. Cowden KD and Simon MC. The bHLH/PAS factor MOP3 does not participate in hypoxia responses. Biochem Biophys Res Commun 290: 1228-1236, 2002.
44. Da Silva JL, Lacombe C, Bruneval P, Casadevall N, Leporrier M, Camilleri JP, Bariety J, Tambourin P, and Varet B. Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia. Blood 75: 577-582, 1990.
45. Dai S, Huang ML, Hsu CY, and Chao KS. Inhibition of hypoxia inducible factor 1α causes oxygen-independent cytotoxicity and induces p53 independent apoptosis in glioblastoma cells. Int J Radiat Oncol Biol Phys 55: 1027-1036, 2003.
46. Dameron KM, Volpert OV, Tainsky MA, and Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584, 1994.
47. Dames SA, Martinez-Yamout M, De Guzman RN, Dyson HJ, and Wright PE. From the Cover: structural basis for Hif-1α/CBP recognition in the cellular hypoxic response. Proc NatlAcad Sci USA 99: 5271-5276, 2002.
48. D'Angelo G, Duplan E, Vigne P, and Frelin C. Cyclosporin A prevents the hypoxic adaptation by activating hypoxia-inducible factor-1α Pro-564 hydroxylation. J Biol Chem 278: 15406-15411, 2003.
49. Dome JS and Coppes MJ. Recent advances in Wilms tumor genetics. Curr Opin Pediatr 14: 5-11, 2002.
50. Drutel G, Kathmann M, Heron A, Schwartz JC, and Arrang JM. Cloning and selective expression in brain and kidney of ARNT2 homologous to the Ah receptor nuclear translocator (ARNT). Biochem Biophys Res Commun 225: 333-339, 1996.
51. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368-4380, 2002.
52. Ebert BL and Bunn HF. Regulation of transcription by hypoxia requires a multiprotein complex that includes hypoxia-inducible factor 1, an adjacent transcription factor, and p300/CREB binding protein. Mol Cell Biol 18: 4089-4096, 1998.
53. Ema M, Hirota K, Mimura J, Abe H, Yodoi J, Sogawa K, Poellinger L, and Fujii-Kuriyama Y. Molecular mechanisms of transcription activation by HLF and HIF1α in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J 18: 1905-1914, 1999.
54. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, and Ratcliffe PJ. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54, 2001.
55. Fang J, Yan L, Shing Y, and Moses MA. HIF-1α-mediated upregulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Res 61: 5731-5735, 2001.
56. Fatyol K and Szalay AA. The p14ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1α (HIF-1α) and inhibits HIF-1-mediated transcription. J Biol Chem 276: 28421-28429, 2001.
57. Favier J, Plouin PF, Corvol P, and Gasc JM. Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol 161: 1235-1246, 2002.
58. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, and Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1α and insulin-like growth factor 2. Cancer Res 59: 3915-3918, 1999.
59. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 280: C1358-C1366, 2001.
60. Flamme I, Krieg M, and Plate KH. Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2α. Am. J Pathol 153: 25-29, 1998.
61. Fontanini G, Boldrini L, Vignati S, Chine S, Basolo F, Silvestri V, Lucchi M, Mussi A, Angeletti CA, and Bevilacqua G. Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. Eur J Cancer 34: 718-723, 1998.
62. Freedman SJ, Sun ZY, Poy F, Kung AL, Livingston DM, Wagner G, and Eck MJ. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1α. Proc Natl Acad Sci USA 99: 5367-5372, 2002.
63. Fujita Y, Mimata H, Nasu N, Nomura T, Nomura Y, and Nakagawa M. Involvement of adrenomedullin induced by hypoxia in angiogenesis in human renal cell carcinoma. Int J Urol 9: 285-295, 2002.
64. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, and Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277: 38205-38211, 2002.
65. 2 is mediated by hypoxia-inducible factor 1. Cancer Res 63: 2330-2334, 2003.
66. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK, and Seed B. Tumor induction of VEGF promoter activity in stromal cells. Cell 94: 715-725, 1998.
67. Gan Y, Au JL, Lu J, and Wientjes MG. Antiproliferative and cytotoxic effects of geldanamycin, cytochalasin E, suramin and thiacetazone in human prostate xenograft tumor histocultures. Pharm Res 15: 1760-1766, 1998.
68. Gao N, Jiang BH, Leonard SS, Corum L, Zhang Z, Roberts JR, Antonini J, Zheng JZ, Flynn DC, Castranova V, and Shi X. p38 signaling-mediated hypoxia-inducible factor 1α and vascular endothelial growth factor induction by Cr(VI) in DU145 human prostate carcinoma cells. J Biol Chem 277: 45041-45048, 2002.
69. Garayoa M, Martinez A, Lee S, Pio R, An WG, Neckers L, Trepel J, Montuenga LM, Ryan H, Johnson R, Gassmann M, and Cuttitta F. Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol 14: 848-862, 2000.
70. Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, and Harris AL. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 61: 7992-7998, 2001.
71. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, Gatter KC, and Harris AL. Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 85: 881-890, 2001.
72. Gingras AC, Raught B, and Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 15: 807-826, 2001.
73. Giordano FJ and Johnson RS. Angiogenesis: the role of the microenvironment in flipping the switch. Curr Opin Genet Dev 11: 35-40, 2001.
74. Görlach A, Camenisch G, Kvietikova I, Vogt L, Wenger RH, and Gassmann M. Efficient translation of mouse hypoxia-inducible factor-1α under normoxic and hypoxic conditions. Biochim Biophys Acta 1493: 125-134, 2000.
75. Görlach A, Diebold I, Schini-Kerth VB, Berchner-Pfannschmidt U, Roth U, Brandes RP, Kietzmann T, and Busse R. Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: role of the p22(phox)-containing NADPH oxidase. Circ Res 89: 47-54, 2001.
76. Gradin K, McGuire J, Wenger RH, Kvietikova I, Whitelaw ML, Toftgard R, Tora L, Gassmann M, and Poellinger L. Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor. Mol Cell Biol 16: 5221-5231, 1996.
77. Gradin K, Takasaki C, Fujii-Kuriyama Y, and Sogawa K. The transcriptional activation function of the HIF-like factor requires phosphorylation at a conserved threonine. J Biol Chem 277: 23508-23514, 2002.
78. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, and Giaccia AJ. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88-91, 1996.
79. Graven KK, Bellur D, Klahn BD, Lowrey SL, and Amberger E. HIF-2α regulates glyceraldehyde-3-phosphate dehydrogenase expression in endothelial cells. Biochim Biophys Acta 1626: 10-18, 2003.
80. Griffiths JR, McSheehy PM, Robinson SP, Troy H, Chung YL, Leek RD, Williams KJ, Stratford IJ, Harris AL, and Stubbs M. Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1β HIF-1β): evidence of an anabolic role for the HIF-1 pathway. Cancer Res 62: 688-695, 2002.
81. Groulx I and Lee S. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol 22: 5319-5336, 2002.
82. Gu W and Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595-606, 1997.
83. Gu YZ, Moran SM, Hogenesch JB, Wartman L, and Bradfield CA. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3α. Gene Expr 7: 205-213, 1998.
84. Hanahan D and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
85. Hansson LO, Friedler A, Freund S, Rudiger S, and Fersht AR. Two sequence motifs from HIF-1α bind to the DNA-binding site of p53. Proc Natl Acad Sci USA 99: 10305-10309, 2002.
86. Hara S, Hamada J, Kobayashi C, Kondo Y, and Imura N. Expression and characterization of hypoxia-inducible factor (HIF)-3α in human kidney: suppression of HIF-mediated gene expression by HIF-3α. Biochem Biophys Res Commun 287: 808-813, 2001.
87. Harada H, Nakagawa K, Saito M, Kohno S, Nagato S, Furukawa K, Kumon Y, Hamada K, and Ohnishi T. Introduction of wild-type p53 enhances thrombospondin-1 expression in human glioma cells. Cancer Lett 191: 109-119, 2003.
88. Hellwig-Burgel T, Rutkowski K, Metzen E, Fandrey J, and Jelkmann W. Interleukin-1β and tumor necrosis factor-α stimulate DNA binding of hypoxia-inducible factor-1. Blood 94: 1561-1567, 1999.
89. Hewitson KS, McNeill LA, Riordan MV, Tian YM, Bullock AN, Welford RW, Elkins JM, Oldham NJ, Bhattacharya S, Gleadle JM, Ratcliffe PJ, Pugh CW, and Schofield CJ. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 277: 26351-26355, 2002.
90. Hirose K, Morita M, Ema M, Mimura J, Hamada H, Fujii H, Saijo Y, Gotoh O, Sogawa K, and Fujii-Kuriyama Y. cDNA cloning and tissue-specific expression of a novel basic helix-loop-helix/PAS factor (Arnt2) with close sequence similarity to the aryl hydrocarbon receptor nuclear translocator (Amt). Mol Cell Biol 16: 1706-1713, 1996.
91. Hirota K, and Semenza GL. Rac1 activity is required for the activation of hypoxia-inducible factor 1. J Biol Chem 276: 21166-21172, 2001.
92. Ho VT and Bunn HF. Effects of transition metals on the expression of the erythropoietin gene: further evidence that the oxygen sensor is a heme protein. Biochem Biophys Res Commun 223: 175-180, 1996.
93. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, and Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56: 4509-4515, 1996.
94. Hockel M, Schlenger K, Hockel S, Aral B, Schaffer U, and Vaupel P. Tumor hypoxia in pelvic recurrences of cervical cancer. Int J Cancer 79: 365-369, 1998.
95. Hockel M, Schlenger K, Hockel S, and Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 59: 4525-4528, 1999.
96. Hockel M, Schlenger K, Knoop C, and Vaupel P. Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res 51: 6098-6102, 1991.
97. Hockel M, Schlenger K, Mitze M, Schaffer U, and Vaupel P. Hypoxia and radiation response in human tumors. Semin Radiat Oncol 6: 3-9, 1996.
98. Hofer T, Desbaillets I, Hopfl G, Gassmann M, and Wenger RH. Dissecting hypoxia-dependent and hypoxia-independent steps in the HIF-1α activation cascade: implications for HIF-1α gene therapy. FASEB J 15: 2715-2717, 2001.
99. Hogenesch JB, Chan WK, Jackiw VH, Brown RC, Gu YZ, Pray-Grant M, Perdew GH, and Bradfield CA. Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway. J Biol Chem 272: 8581-8593, 1997.
100. Hogenesch JB, Gu YZ, Jain S, and Bradfield CA. The basic-helix-loop-helix-PAS orphan MOP3 forms transcriptionally active complexes with circadian and hypoxia factors. Proc Natl Acad Sci USA 95: 5474-5479, 1998.
101. Höpfl G, Wenger RH, Ziegler U, Stallmach T, Gardelle O, Achermann R, Wergin M, Kaser-Hotz B, Saunders HM, Williams KJ, Stratford IJ, Gassmann M, and Desbaillets I. Rescue of hypoxia-inducible factor-1α-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor. Cancer Res 62: 2962-2970, 2002.
102. Huang J, Zhao Q, Mooney SM, and Lee FS. Sequence determinants in hypoxia-inducible factor-1α for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3. J Biol Chem 277: 39792-39800, 2002.
103. Huang LE, Arany Z, Livingston DM, and Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 271: 32253-32259, 1996.
104. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 95: 7987-7992, 1998.
105. Hur E, Chang KY, Lee E, Lee SK, and Park H. Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1alpha. Mol Pharmacol 59: 1216-1224, 2001.
106. Hur E, Kim HH, Choi SM, Kim JH, Yim S, Kwon HJ, Choi Y, Kim DK, Lee MO, and Park H. Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1α/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol. Mol Pharmacol 62: 975-982, 2002.
107. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, and Greenberg NM. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 61: 2736-2743, 2001.
108. Ikeda M and Nomura M. cDNA cloning and tissue-specific expression of a novel basic helix-loop-helix/PAS protein (BMAL1) and identification of alternatively spliced variants with alternative translation initiation site usage. Biochem Biophys Res Commun 233: 258-264, 1997.
109. Iliopoulos O, Kibel A, Gray S, and Kaelin WG Jr. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1: 822-826, 1995.
110. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, and Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway. J Biol Chem 277: 29936-29944, 2002.
111. Itoh T, Namba T, Fukuda K, Semenza GL, and Hirota K. Reversible inhibition of hypoxia-inducible factor 1 activation by exposure of hypoxic cells to the volatile anesthetic halothane. FEBS Lett 509: 225-229, 2001.
112. 2 sensing. Science 292: 464-468, 2001.
113. 2 homeostasis by hypoxia-inducible factor 1α. Genes Dev 12: 149-162, 1998.
114. Iyer NV, Leung SW, and Semenza GL. The human hypoxia-inducible factor 1α gene: HIF1A structure and evolutionary conservation. Genomics 52: 159-165, 1998.
115. 2-regulated prolyl hydroxylation. Science 292: 468-472, 2001.
116. Jain RK. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J Control Release 74: 7-25, 2001.
117. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 29: 3-9, 2002.
118. Jain S, Maltepe E, Lu MM, Simon C, and Bradfield CA. Expression of ARNT, ARNT2, HIF1α, HIF2α and Ah receptor mRNAs in the developing mouse. Mech Dev 73: 117-123, 1998.
119. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, Yoo MA, Song EJ, Lee KJ, and Kim KW. Regulation and destabilization of HIF-1α by ARD1-mediated acetylation. Cell 111: 709-720, 2002.
120. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, and Gassmann M. Induction of HIF-1α in response to hypoxia is instantaneous. FASEB J 15: 1312-1314, 2001.
121. Jiang BH, Agani F, Passaniti A, and Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 57: 5328-5335, 1997.
122. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, and Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12: 363-369, 2001.
123. Jiang BH, Rue E, Wang GL, Roe R, and Semenza GL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271: 17771-17778, 1996.
124. 2 tension. Am J Physiol Cell Physiol 271: C1172-C1180, 1996.
125. Jung YJ, Isaacs JS, Lee S, Trepel J, and Neckers L. Microtubule disruption utilizes an NFκB-dependent pathway to stabilize HIF-1α protein. J Biol Chem 278: 7445-7452, 2003.
126. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2: 673-682, 2002.
127. Kallio PJ, Okamoto K, O'Brien S, Carrero P, Makino Y, Tanaka H, and Poellinger L. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1α. EMBO J 17: 6573-6586, 1998.
128. Kallio PJ, Wilson WJ, O'Brien S, Makino Y, and Poellinger L. Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J Biol Chem 274: 6519-6525, 1999.
129. Kaluz S, Kaluzova M, Chrastina A, Olive PL, Pastorekova S, Pastorek J, Lerman MI, and Stanbridge EJ. Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor la stabilization: a role for phosphatidylinositol 3′-kinase. Cancer Res 62: 4469-4477, 2002.
130. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, and Conaway JW. Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 97: 10430-10435, 2000.
131. Kappel A, Ronicke V, Damert A, Flamme I, Risau W, and Breier G. Identification of vascular endothelial growth factor (VEGF) receptor-2 (Flk-1) promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice. Blood 93: 4284-4292, 1999.
132. Karni R, Dor Y, Keshet E, Meyuhas O, and Levitzki A. Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1α expression under normoxia. J Biol Chem 277: 42919-42925, 2002.
133. Katschinski DM, Le L, Heinrich D, Wagner KF, Hofer T, Schindler SG, and Wenger RH. Heat induction of the unphosphorylated form of hypoxia-inducible factor-1a is dependent on heat shock protein-90 activity. J Biol Chem 277: 9262-9267, 2002.
134. Kayama T, Yoshimoto T, Fujimoto S, and Sakurai Y. Intratumoral oxygen pressure in malignant brain tumor. J Neurosurg 74: 55-59, 1991.
135. Keith B, Adelman DM, and Simon MC. Targeted mutation of the murine arylhydrocarbon receptor nuclear translocator 2 (Arnt2) gene reveals partial redundancy with Arnt. Proc Natl Acad Sci USA 98: 6692-6697, 2001.
136. Khatua S, Peterson KM, Brown KM, Lawlor C, Santi MR, LaFleur B, Dressman D, Stephan DA, and MacDonald TJ. Overexpression of the EGFR/FKBP12/HIF-2α pathway identified in childhood astrocytomas by angiogenesis gene profiling. Cancer Res 63: 1865-1870, 2003.
137. Kivirikko KI and Pihlajaniemi T. Collagen hydroxylases and the protein disulfide isomerase subunit of prolyl 4-hydroxylases. Adv Enzymol Relat Areas Mol Biol 72: 325-398, 1998.
138. Knowles HJ, Raval RR, Harris AL, and Ratcliffe PJ. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res 63: 1764-1768, 2003.
139. Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci USA 90: 10914-10921, 1993.
140. Kondo K, Klco J, Nakamura E, Lechpammer M, and Kaelin WG. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1: 237-246, 2002.
141. Koshikawa N, Iyozumi A, Gassmann M, and Takenaga K. Constitutive upregulation of hypoxia-inducible factor-1α mRNA occurring in highly metastatic lung carcinoma cells leads to vascular endothelial growth factor overexpression upon hypoxic exposure. Oncogene 22: 6717-6724, 2003.
142. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Turley H, Talks K, Gatter KC, and Harris AL. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 53: 1192-1202, 2002.
143. Koukourakis MI, Giatromanolaki A, Skarlatos J, Corti L, Blandamura S, Piazza M, Gatter KC, and Harris AL. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 61: 1830-1832, 2001.
144. Krek W. VHL takes HIF's breath away. Nat Cell Biol 2: E121-123, 2000.
145. Krieg M, Haas R, Brauch H, Acker T, Flamme I, and Plate KH. Up-regulation of hypoxia-inducible factors HIF-1α and H1F-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19: 5435-5443, 2000.
146. Krieg M, Marti HH, and Plate KH. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Blood 92: 3388-3393, 1998.
147. Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P, and Semenza GL. Regulation of colon
148. Kruger EA, Blagosklonny MV, Dixon SC, and Figg WD. UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response. Invasion Metastasis 18: 209-218, 1998.
149. Kung AL, Wang S, Klco JM, Kaelin WG, and Livingston DM. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 6: 1335-1340, 2000.
150. Kurebayashi J, Otsuki T, Kurosumi M, Soga S, Akinaga S, and Sonoo H. A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1α and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts. Jpn J Cancer Res 92: 1342-1351, 2001.
151. Lando D, Gorman JJ, Whitelaw ML, and Peet DJ. Oxygen-dependent regulation of hypoxia-inducible factors by prolyl and asparaginyl hydroxylation. Eur J Biochem 270: 781-790, 2003.
152. Lando D, Peet DJ, Whelan DA, Gorman JJ, and Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295: 858-861, 2002.
153. Laughner E, Taghavi P, Chiles K, Mahon PC, and Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995-4004, 2001.
154. Lee PJ, Jiang BH, Chin BY, Iyer NV, Alam J, Semenza GL, and Choi AM. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem 272: 5375-5381, 1997.
155. Leek RD, Talks KL, Pezzella F, Turley H, Campo L, Brown NS, Bicknell R, Taylor M, Gatter KC, and Harris AL. Relation of hypoxia-inducible factor-2α (HIF-2α) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in human breast cancer. Cancer Res 62: 1326-1329, 2002.
156. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, and Livingston DM. Binding and modulation of p53 by p300/CBP coactivators. Nature 387: 823-827, 1997.
157. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, Pastorek J, Ratcliffe PJ, Stratford IJ, and West CM. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61: 6394-6399, 2001.
158. Lu H, Forbes RA, and Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 277: 23111-23115, 2002.
159. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, and Glannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3: 363-375, 2003.
160. Mabjeesh N J, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, and Zhong H. Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells. Cancer Res 62: 2478-2482, 2002.
161. Mack FA, Rathmell WK, Arsham AM, Gnarra J, Keith B, and Simon MC. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell 3: 75-88, 2003.
162. Mahon PC, Hirota K, and Semenza GL. FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15: 2675-2686, 2001.
163. Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H, Cao Y, Berkenstam A, and Poellinger L. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414: 550-554, 2001.
164. Makino Y, Kanopka A, Wilson WJ, Tanaka H, and Poellinger L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3α locus. J Biol Chem 277: 32405-32408, 2002.
165. Maltepe E, Keith B, Arsham AM, Brorson JR, and Simon MC. The role of ARNT2 in tumor angiogenesis and the neural response to hypoxia. Biochem Biophys Res Commun 273: 231-238, 2000.
166. Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ, and Maxwell PH. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1: 459-468, 2002.
167. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, and Klausner RD. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1: 247-255, 2002.
168. Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, and Hendrix MJ. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 14: 176-186, 1996.
169. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, and Ratcliffe PJ. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94: 8104-8109, 1997.
170. Mayerhofer M, Valent P, Sperr WR, Griffin JD, and Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100: 3767-3775, 2002.
171. Maynard MA, Qi H, Chung J, Lee EH, Kondo Y, Hara S, Conaway RC, Conaway JW, and Ohh M. Multiple splice variants of the human HIF-3α locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem 278: 11032-11040, 2003.
172. Mayo MW, Wang CY, Drouin SS, Madrid LV, Marshall AF, Reed JC, Weissman BE, and Baldwin AS. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J 18: 3990-4003, 1999.
173. Mazure NM, Chen EY, Laderoute KR, and Giaccia AJ. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90: 3322-3331, 1997.
174. Melillo G, Musso T, Sica A, Taylor LS, Cox GW, and Varesio L. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 182: 1683-1693, 1995.
175. Metzen E, Berchner-Pfannschmidt U, Stengel P, Marxsen JH, Stolze I, Klinger M, Huang WQ, Wotzlaw C, Hellwig-Burgel T, Jelkmann W, Acker H, and Fandrey J. Intracellular localisation of human HIF-1α hydroxylases: implications for oxygen sensing. J Cell Sci 116: 1319-1326, 2003.
176. Mie Lee Y, Kim SH, Kim HS, Jin Son M, Nakajima H, Jeong Kwon H, and Kim KW. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1α activity. Biochem Biophys Res Commun 300: 241-246, 2003.
177. Minchenko A, Leshchinsky I, Opentanova I, Sang N, Srinivas V, Armstead V, and Caro J. Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J Biol Chem 277: 6183-6187, 2002.
178. Minet E, Michel G, Mottet D, Piret JP, Barbieux A, Raes M, and Michiels C. c-JUN gene induction and AP-1 activity is regulated by a JNK-dependent pathway in hypoxic HepG2 cells. Exp Cell Res 265: 114-124, 2001.
179. Mottet D, Dumont V, Deccache Y, Demazy C, Ninane N, Raes M, and Michiels C. Regulation of HIF-1α protein level during hypoxic conditions by the PI3K/AKT/GSK3β pathway in HepG2 cells. J Biol Chem 278: 31277-31285, 2003.
180. Mukhopadhyay D, Tsiokas L, and Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 55: 6161-6165, 1995.
181. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, and Kaelin WG. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2: 423-427, 2000.
182. Olive PL, Aquino-Parsons C, MacPhail SH, Liao SY, Raleigh JA, Lerman MI, and Stanbridge EJ. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 61: 8924-8929, 2001.
183. Onita T, Ji PG, Xuan JW, Sakai H, Kanetake H, Maxwell PH, Fong GH, Gabril MY, Moussa M, and Chin JL. Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2α correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Clin Cancer Res 8: 471-480, 2002.
184. Palmer LA, Semenza GL, Stoler MH, and Johns RA. Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1. Am J Physiol Lung Cell Mol Physiol 274: L212-L219, 1998.
185. Parkkila S, Rajaniemi H, Parkkila AK, Kivela J, Waheed A, Pastorekova S, Pastorek J, and Sly WS. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc Natl Acad Sci USA 97: 2220-2224, 2000.
186. Post DE and Van Meir EG. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 22: 2065-2072, 2003.
187. Pouyssegur J, Volmat V, and Lenormand P. Fidelity and spatiotemporal control in MAP kinase (ERKs) signalling. Biochem Pharmacol 64: 755-763, 2002.
188. Pugh CW, O'Rourke JF, Nagao M, Gleadle JM, and Ratcliffe PJ. Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. J Biol Chem 272: 11205-11214, 1997.
189. Pugh CW and Ratcliffe PJ. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin Cancer Biol 13: 83-89, 2003.
190. Rampling R, Cruickshank G, Lewis AD, Fitzsimmons SA, and Workman P. Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 29: 427-431, 1994.
191. Raught B, Gingras AC, and Sonenberg N. The target of rapamycin (TOR) proteins. Proc Natl Acad Sci USA 98: 7037-7044, 2001.
192. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL, and Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev 14: 34-44, 2000.
193. Richard DE, Berra E, Gothie E, Roux D, and Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J Biol Chem 274: 32631-32637, 1999.
194. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, and Downward J. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370: 527-532, 1994.
195. Rofstad EK, Sundfor K, Lyng H, and Trope CG. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer 83: 354-359, 2000.
196. Rozhin J, Sameni M, Ziegler G, and Sloane BF. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res 54: 6517-6525, 1994.
197. Ruan H, Wang J, Hu L, Lin CS, Lamborn KR, and Deen DF. Killing of brain tumor cells by hypoxia-responsive element mediated expression of BAX. Neoplasia (New York) 1: 431-437, 1999.
198. Ryan HE, Lo J, and Johnson RS. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J 17: 3005-3015, 1998.
199. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM, and Johnson RS. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res 60: 4010-4015, 2000.
200. Salceda S and Caro J. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272: 22642-22647, 1997.
201. Sang N, Fang J, Srinivas V, Leshchinsky I, and Caro J. Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1α is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. Mol Cell Biol 22: 2984-2992, 2002.
202. Sang N, Stiehl DP, Bohensky J, Leshchinsky I, Srinivas V, and Caro J. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem 278: 14013-14019, 2003.
203. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, and Oberhuber G. Overexpression of hypoxia-inducible factor 1α is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8: 1831-1837, 2002.
204. Schmaltz C, Hardenbergh PH, Wells A, and Fisher DE. Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol Cell Biol 18: 2845-2854, 1998.
205. Schmelzle T and Hall MN. TOR, a central controller of cell growth. Cell 103: 253-262, 2000.
206. Scott PH, Paul A, Belham CM, Peacock AJ, Wadsworth RM, Gould GW, Welsh D, and Plevin R. Hypoxic stimulation of the stress-activated protein kinases in pulmonary artery fibroblasts. Am J Respir Crit Care Med 158: 958-962, 1998.
207. Seko Y, Takahashi N, Tobe K, Kadowaki T, and Yazaki Y. Hypoxia and hypoxia/reoxygenation activate p65PAK, p38 mitogen-activated protein kinase (MAPK), and stress-activated protein kinase (SAPK) in cultured rat cardiac myocytes. Biochem Biophys Res Commun 239: 840-844, 1997.
208. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 64: 993-998, 2002.
209. Semenza GL. HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev 19: 59-65, 2000.
210. Shemirani B and Crowe DL. Hypoxic induction of HIF-1α and VEGF expression in head and neck squamous cell carcinoma lines is mediated by stress activated protein kinases. Oral Oncol 38: 251-257, 2002.
211. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2: 731-737, 2001.
212. Shibata T, Giaccia AJ, and Brown JM. Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther 7: 493-498, 2000.
213. Shibata T, Giaccia AJ, and Brown JM. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia 4: 40-48, 2002.
214. Sodhi A, Montaner S, Miyazaki H, and Gutkind JS. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1α in rasV12 upregulation of VEGF. Biochem Biophys Res Commun 287: 292-300, 2001.
215. Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, and Harris AL. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res 61: 6669-6673, 2001.
216. Srinivas V, Zhang LP, Zhu XH, and Caro J. Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor α (HIF-α) proteins. Biochem Biophys Res Commun 260: 557-561, 1999.
217. Stewart M, Talks K, Leek R, Turley H, Pezzella F, Harris A, and Gatter K. Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2 and CA IX in non-Hodgkin's lymphoma. Histopathology 40: 253-260, 2002.
218. Stohrer M, Boucher Y, Stangassinger M, and Jain RK. Oncotic pressure in solid tumors is elevated. Cancer Res 60: 4251-4255, 2000.
219. Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DA, Bauer C, Gassmann M, and Candinas D. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J 15: 2445-2453, 2001.
220. Stubbs M, McSheehy PM, Griffiths JR, and Bashford CL. Causes and consequences of tumour acidity and implications for treatment. Mol Med Today 6: 15-19, 2000.
221. Sun X, Kanwar JR, Leung E, Lehnert K, Wang D, and Krissansen GW. Gene transfer of antisense hypoxia inducible factor-1α enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther 8: 638-645, 2001.
222. Sutter CH, Laughner E, and Semenza GL. Hypoxia-inducible factor 1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc Natl Acad Sci USA 97: 4748-4753, 2000.
223. Suzuki H, Tomida A, and Tsuruo T. Dephosphorylated hypoxia-inducible factor 1α as a mediator of p53-dependent apoptosis during hypoxia. Oncogene 20: 5779-5788, 2001.
224. Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Taub N, Harris AL, and O'Byrne KJ. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 21: 473-482, 2003.
225. Takahashi Y, Bucana CD, Cleary KR, and Ellis LM. p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int J Cancer 79: 34-38, 1998.
226. Takahata S, Sogawa K, Kobayashi A, Ema M, Mimura J, Ozaki N, and Fujii-Kuriyama Y. Transcriptionally active heterodimer formation of an Arnt-like PAS protein, Arnt3, with HIF-1a, HLF, and clock. Biochem Biophys Res Commun 248: 789-794, 1998.
227. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, and Harris AL. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157: 411-421, 2000.
228. Tian H, Hammer RE, Matsumoto AM, Russell DW, and McKnight SL. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 12: 3320-3324, 1998.
229. Tian H, McKnight SL, and Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11: 72-82, 1997.
230. Toyama K, Fujiyama N, Suzuki H, Chen TP, Tamaoki N, and Ueyama Y. Erythropoietin levels in the course of a patient with erythropoietin-producing renal cell carcinoma and transplantation of this tumor in nude mice. Blood 54: 245-253, 1979.
231. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, and Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 277: 27975-27981, 2002.
232. Turcotte S, Desrosiers RR, and Beliveau R. HIF-1α mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma. J Cell Sci 116: 2247-2260, 2003.
233. Turner KJ, Moore JW, Jones A, Taylor CF, Cuthbert-Heavens D, Han C, Leek RD, Gatter KC, Maxwell PH, Ratcliffe PJ, Cranston D, and Harris AL. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62: 2957-2961, 2002.
234. Van Meir EG, Polverini PJ, Chazin VR, Su Huang HJ, de Tribolet N, and Cavenee WK. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet 8: 171-176, 1994.
235. Vaupel P, Schlenger K, Knoop C, and Hockel M. Oxygenation of human tumors: evaluation of fissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 51: 3316-3322, 1991.
236. Vivanco I and Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
237. Volm M and Koomagi R. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res 20: 1527-1533, 2000.
238. Wagner KD, Wagner N, Wellmann S, Schley G, Bondke A, Theres H, and Scholz H. Oxygen-regulated expression of the Wilms' tumor suppressor Wt1 involves hypoxia-inducible factor-1 (HIF-1) (Abstract). FASEB J 8: 8, 2003.
239. Wang GL and Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 82: 3610-3615, 1993.
240. Wang GL and Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270: 1230-1237, 1995.
241. Wang W, Merrill MJ, and Borchardt RT. Vascular endothelial growth factor affects permeability of brain microvessel endothelial cells in vitro. Am J Physiol Cell Physiol 271: C1973-C1980, 1996.
242. Warburg O. The Metabolism of Tumors (translated from the German edition by F. Dickens). London: Constable, 1930.
243. Warnecke C, Griethe W, Weidemann A, Jurgensen JS, Willam C, Bachmann S, Ivashchenko Y, Wagner I, Frei U, Wiesener M, and Eckardt KU. Activation of the hypoxia-inducible factor pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors (Abstract). FASEB J 22: 22, 2003.
244. Wenger RH. Mammalian oxygen sensing, signalling and gene regulation. J Exp Biol 203: 1253-1263, 2000.
245. Wenger RH, Camenisch G, Desbaillets I, Chilov D, and Gassmann M. Up-regulation of hypoxia-inducible factor-1α is not sufficient for hypoxic/anoxic p53 induction. Cancer Res 58: 5678-5680, 1998.
246. Wenger RH and Gassmann M. Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem 378: 609-616, 1997.
247. Wiesener MS, Jurgensen JS, Rosenberger C, Scholze C, Horstrup JH, Warnecke C, Mandriota S, Bechmann I, Frei UA, Pugh CW, Ratcliffe PJ, Bachmann S, Maxwell PH, and Eckardt KU. Widespread, hypoxia-inducible expression of HIF-2α in distinct cell populations of different organs (Abstract). FASEB J 17: 17, 2002.
248. Wiesener MS, Seyfarth M, Warnecke C, Jurgensen JS, Rosenberger C, Morgan NV, Maher ER, Frei U, and Eckardt KU. Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood 99: 3562-3565, 2002.
249. Wiesener MS, Turley H, Allen WE, Willam C, Eckardt KU, Talks KL, Wood SM, Gatter KC, Harris AL, Pugh CW, Ratcliffe PJ, and Maxwell PH. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1α. Blood 92: 2260-2268, 1998.
250. Willam C, Masson N, Tian YM, Mahmood SA, Wilson MI, Bicknell R, Eckardt KU, Maxwell PH, Ratcliffe PJ, and Pugh CW. Peptide blockade of HIFα degradation modulates cellular metabolism and angiogenesis (Abstract). Proc Natl Acad Sci USA 29: 29, 2002.
251. Williams KJ, Telfer BA, Airley RE, Peters HP, Sheridan MR, van der Kogel AJ, Harris AL, and Stratford IJ. A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumorigenesis. Oncogene 21: 282-290, 2002.
252. Wright G, Higgin JJ, Raines RT, Steenbergen C, and Murphy E. Activation of the prolyl hydroxylase oxygen-sensor results in induction of GLUT1, HO-1, NOS-2 proteins, and confers protection from metabolic inhibition to cardiomyocytes (Abstract). J Biol Chem 20: 20, 2003.
253. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, and Harris AL. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60: 7075-7083, 2000.
254. Xia G, Kageyama Y, Hayashi T, Kawakami S, Yoshida M, and Kihara K. Regulation of vascular endothelial growth factor transcription by endothelial PAS domain protein 1 (EPAS 1) and possible involvement of EPAS1 in the angiogenesis of renal cell carcinoma. Cancer 91: 1429-1436, 2001.
255. Yamashita K, Discher DJ, Hu J, Bishopric NH, and Webster KA. Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, and p300/CBP. J Biol Chem 276: 12645-12653, 2001.
256. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, and Park JW. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95: 516-525, 2003.
257. Yu F, White SB, Zhao Q, and Lee FS. Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein. Cancer Res 61: 4136-4142, 2001.
258. Yu JL, Rak JW, Carmeliet P, Nagy A, Kerbel RS, and Coomber BL. Heterogeneous vascular dependence of tumor cell populations. Am J Pathol 158: 1325-1334, 2001.
259. Yuan A, Yu CJ, Luh KT, Kuo SH, Lee YC, and Yang PC. Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J Clin Oncol 20: 900-910, 2002.
260. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, and Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93: 14765-14770, 1996.
261. Yuan Y, Hilliard G, Ferguson T, and Millhorn DE. Cobalt inhibits the interaction between hypoxia inducible factor-α and von Hippel-Lindau protein by direct binding to hypoxia inducible factor-α (Abstract). J Biol Chem 26: 26, 2003.
262. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, and Semenza GL. Expression of hypoxia-inducible factor 1α in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88: 2606-2618, 2000.
263. Zaman K, Ryu H, Hall D, O'Donovan K, Lin KI, Miller MP, Marquis JC, Baraban JM, Semenza GL, and Ratan RR. Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin. J Neurosci 19: 9821-9830, 1999.
264. Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, and Cohen B. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBO J 17: 5085-5094, 1998.
265. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, and Semenza GL. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545, 2000.
266. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, and Simons JW. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999.
267. Zudaire E, Marti, nez A, and Cuttitta F. Adrenomedullin and cancer. Regul Pept 112: 175-183, 2003.
268. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, Stokoe D, and Giaccia AJ. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14: 391-396, 2000.